CoolFace
Datasetpublic

OpenPharma/pharma-kb-obesity

Pharma KB — Obesity Drug Landscape A structured pharmaceutical knowledge base covering the obesity drug pipeline — compiled from public regulatory, clinical, and scientific sources. Designed for RAG pipelines, competitive intelligence workflows, and pharma-domain LLM fine-tuning. Overview Indication Obesity (ICD: E66) Drug articles 285 (all phases, launched through discovery) Company articles 248 Target articles 35 Full content size ~11 MB… See the full description on the dataset page: https://huggingface.co/datasets/OpenPharma/pharma-kb-obesity.

sourceHugging Facecc-by-nc-4.0updated 3mo agoView on Hugging Face
0likes271downloads
Dataset Card

Pharma KB — Obesity Drug Landscape

A structured pharmaceutical knowledge base covering the obesity drug pipeline — compiled from public regulatory, clinical, and scientific sources. Designed for RAG pipelines, competitive intelligence workflows, and pharma-domain LLM fine-tuning.

Obesity knowledge graph — full network view showing drugs (green), companies (red), targets (blue) and indications (yellow)

Obesity knowledge graph — detail view centered on glucagon-like-peptide-1-receptor

Overview

IndicationObesity (ICD: E66)
Drug articles285 (all phases, launched through discovery)
Company articles248
Target articles35
Full content size~11 MB of structured markdown
CompiledJune 2026
Update cadenceWeekly refresh
LicenseCC BY-NC 4.0

Phase distribution (285 drugs):

PhaseCountDescription
Launched12Approved and marketed
Registered2Approved in ≥1 market, not yet launched
Filed8Submitted for regulatory review
Phase 332Pivotal trials
Phase 299Proof-of-concept / dose-finding
Phase 1117First-in-human / safety
Discovery7Pre-IND / preclinical

Top pipeline positions (activity score, 0–100):

  • Eli Lilly and Company — 86.84
  • Novo Nordisk — 86.44
  • Hanmi Pharmaceutical — 34.39

Sample Article

Drug articles are markdown files with structured frontmatter and narrative body:

yaml
---
title: semaglutide (subcutaneous, diabetes/obesity/NASH), Novo Nordisk
type: drug
slug: semaglutide
phase: Launched
originator: Novo Nordisk A/S
mechanism: Glucagon-like peptide 1 receptor agonist
indication_count: 10
fda_approval_count: 4
ct_trial_count: 215
targets:
- glucagon-like-peptide-1-receptor
indications:
- obesity
- non-insulin-dependent-diabetes
- metabolic-dysfunction-associated-steatohepatitis
# ... more fields
---

The body covers mechanism of action, clinical trial history, regulatory milestones (FDA/EMA/PMDA), competitive context, deal activity, and preprint evidence.

Dataset Structure

pharma-kb-obesity/
├── indications/
│   └── obesity.md              # Landscape overview, pipeline phases, deal velocity
├── drugs/                      # 277 drug articles — all phases
│   ├── semaglutide.md
│   ├── tirzepatide.md
│   ├── cagrilintide.md
│   └── ...
├── companies/                  # 248 company articles with pipeline positions
│   ├── eli-lilly.md
│   ├── novo-nordisk.md
│   └── ...
├── targets/                    # 35 target articles
│   ├── glucagon-like-peptide-1-receptor.md
│   ├── gastric-inhibitory-polypeptide-receptor.md
│   └── ...
├── MANIFEST.md                 # Resolve URLs for all 569 articles (for direct fetch)
└── data/
    └── train.parquet           # Structured index — one row per entity

Each article is a markdown file with YAML frontmatter and a narrative body covering mechanism, clinical status, regulatory history, and competitive context.

Usage

Load the index

python
from datasets import load_dataset

ds = load_dataset("OpenPharma/pharma-kb-obesity", split="train")
df = ds.to_pandas()

# Filter: Phase 3 drugs
phase3 = df[(df["entity_type"] == "drug") & (df["phase"] == "Phase 3")]
print(phase3[["slug", "title", "mechanism", "originator"]])

Fetch any article directly

Every article has a stable resolve URL:

https://huggingface.co/datasets/OpenPharma/pharma-kb-obesity/resolve/main/companies/eli-lilly.md
https://huggingface.co/datasets/OpenPharma/pharma-kb-obesity/resolve/main/drugs/tirzepatide.md
https://huggingface.co/datasets/OpenPharma/pharma-kb-obesity/resolve/main/indications/obesity.md

A full listing of all 569 resolve URLs is available at `MANIFEST.md`.

Clone for full article access

bash
git clone https://huggingface.co/datasets/OpenPharma/pharma-kb-obesity

RAG pipeline

python
from huggingface_hub import snapshot_download
from pathlib import Path

repo_path = Path(snapshot_download("OpenPharma/pharma-kb-obesity"))

# Load all articles as documents
documents = []
for md_file in repo_path.rglob("*.md"):
    documents.append({
        "text": md_file.read_text(),
        "source": str(md_file.relative_to(repo_path)),
    })

# Feed into LlamaIndex, LangChain, or any embedding pipeline

Read a specific article

python
import yaml
from pathlib import Path

def parse_article(path):
    content = Path(path).read_text()
    _, fm_raw, body = content.split("---", 2)
    return yaml.safe_load(fm_raw), body

fm, body = parse_article(repo_path / "drugs/semaglutide.md")
print(fm["phase"], fm["mechanism"])
print(body[:500])

What's in Each Article

Drug articles include:

  • Phase, mechanism of action, originator, indication coverage
  • FDA approval history (approvals, label cross-checks)
  • Clinical trial counts (ClinicalTrials.gov cross-referenced)
  • Regulatory conflicts and data quality flags
  • Aliases (brand names, INN variants, trial codes)
  • Industry research attention — rolling 7-day attention rank and relative research activity vs. peers across the obesity landscape

Company articles include:

  • Drug count and phase distribution per indication
  • Activity score and tier across indications
  • Deal counts and partnership history
  • Investment Profile — public/private status, ticker (exchange + symbol), total capital raised, latest funding round, key investors, and recent pipeline/deal developments sourced from public financial data
  • Competitive drug watchlist — the drugs this organization viewed most over the trailing 7-day window (predominantly other companies' drugs, surfacing competitive interest)

Target articles include:

  • Gene symbol, protein family, disease associations
  • Drugs targeting this mechanism with phase summary
  • Literature and patent coverage notes

Indication article includes:

  • Full pipeline phase distribution and trend analysis
  • Company activity rankings with scores
  • Mechanism class distribution (GLP-1 RA, GIP RA, GCGR, amylin, etc.)
  • Deal velocity and top deal activity by type
  • Industry research activity — ranked heatmap of research attention across top drugs in the landscape for the trailing 7-day window

Structured Index Schema

data/train.parquet — one row per entity (569 rows total):

ColumnEntity typesDescription
entity_typealldrug, company, target, indication
slugallURL-safe identifier
titleallDisplay name
compiled_atallCompilation timestamp
phasedrugDevelopment phase
mechanismdrugMechanism of action
originatordrugOriginating company
indication_countdrugNumber of tracked indications
fda_approval_countdrugFDA-approved applications
ct_trial_countdrugClinicalTrials.gov trial count
top_companyindicationTop-ranked company by activity score
research_attention_rankdrugGlobal attention rank (1 = most researched)
research_views_7ddrugTotal views in the trailing 7-day window
research_unique_orgsdrugNumber of distinct organizations that viewed this drug
research_trend_pctdrugWeek-over-week change in views (%, signed: positive = rising)
investment_statuscompanyPublic · EXCHANGE: TICKER, Private, or Acquired by …
tickercompanyStock ticker symbol (public companies only)
exchangecompanyStock exchange (e.g. NYSE, NASDAQ, KOSDAQ)
total_raisedcompanyTotal disclosed capital raised (private companies)
latest_roundcompanyMost recent disclosed funding round (e.g. Series B · $215M)
watchlist_total_views_7dcompanyTotal page-views the organization generated across all drugs it researched in the trailing 7-day window (predominantly other companies' drugs, not its own pipeline)
watchlist_drug_countcompanyNumber of distinct drugs the organization viewed in the trailing 7-day window
watchlist_top_drugcompanyThe single drug the organization viewed most in the trailing 7-day window
landscape_total_views_7dindicationTotal research activity across all drugs in the indication
landscape_active_orgs_7dindicationNumber of organizations actively researching the indication

Data Sources

This dataset is synthesized from the following public sources:

  • ClinicalTrials.gov — trial counts, recruitment status, phase mapping
  • FDA — drug approvals, labels, FAERS, patents
  • EMA — European approvals and regulatory milestones
  • PubMed — scientific literature
  • ChEMBL — mechanism of action, ADMET, structure data
  • bioRxiv / medRxiv — preprints
  • UniProt — target biology
  • Open Targets — disease-target associations

All data is synthesized and structured — not a direct export from any single source.

Releases

VersionDateArticlesNotes
v2026.06.062026-06-06569Investment Profile for 215 companies — public/private status, ticker, funding rounds, key investors, recent developments
v2026.06.052026-06-05561Initial release

More Indications

Additional indication datasets (MASLD/NASH, cardiovascular, oncology) are in progress under the OpenPharma organization.

License

CC BY-NC 4.0 — free for research and non-commercial use with attribution.

Citation

If you use this dataset in your work, please cite:

@dataset{pharma-kb-obesity-2026,
  title   = {Pharma KB — Obesity Drug Landscape},
  year    = {2026},
  url     = {https://huggingface.co/datasets/OpenPharma/pharma-kb-obesity},
  license = {CC BY-NC 4.0}
}